Share Name Share Symbol Market Type Share ISIN Share Description
Innovaderma Plc LSE:IDP London Ordinary Share GB00BT9PTW34 ORD EUR0.10
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50 -5.95% 39.50 166,542 16:01:50
Bid Price Offer Price High Price Low Price Open Price
39.00 40.00 42.00 39.50 42.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 10.12 1.11 5.51 7.7 6
Last Trade Time Trade Type Trade Size Trade Price Currency
16:38:39 O 56,644 39.00 GBX

Innovaderma (IDP) Latest News

More Innovaderma News
Innovaderma Investors    Innovaderma Takeover Rumours

Innovaderma (IDP) Discussions and Chat

Innovaderma Forums and Chat

Date Time Title Posts
20/1/202118:38Innovaderma - Global Brands and Huge Markets23,131
11/8/201812:02Things to note3
11/8/201812:02Time to Look at InnovaDerma (IDP)3
11/8/201812:02Some interesting posts1

Add a New Thread

Innovaderma (IDP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-01-25 16:38:4039.0056,64422,091.16O
2021-01-25 16:29:5639.601,236489.46O
2021-01-25 16:10:3039.60900356.40O
2021-01-25 16:02:5339.004,1761,628.64O
2021-01-25 16:01:4239.001,000390.00O
View all Innovaderma trades in real-time

Innovaderma (IDP) Top Chat Posts

Innovaderma Daily Update: Innovaderma Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker IDP. The last closing price for Innovaderma was 42p.
Innovaderma Plc has a 4 week average price of 36.50p and a 12 week average price of 36.50p.
The 1 year high share price is 90p while the 1 year low share price is currently 30p.
There are currently 14,496,633 shares in issue and the average daily traded volume is 240,726 shares. The market capitalisation of Innovaderma Plc is £5,726,170.04.
kinwah: No need for the debenture as the loan should be replaced quickly with equity from a placing/rights issue and as a director Ward should have pushed the board to do that at an earlier stage. Just as well IDP are not on AIM with Finncapp as the NOMAD as Geoff Nash at Finncapp would have got an angry phone call from me for signing it off. It is a reminder to investors that companies with standard listings on the LSE are much less regulated than companies on AIM.
lord loads of lolly: teddy boy 1 - how very prescient of you (look it up). Oh and it’s IDP actually. Not IPD. Hope you told your kids to sell the right share?
eezymunny: No Molatov kid, it's a question of whether "women" will buy IDP products or some other products...
deanowls: He is talking about the value placed on businesses such as this one. I posted the below on CRL who I believe could get value out of IDP and certainly know how to engage with investors and deliver growth. The question for me is who could they look to buy, obviously there are private companies that I am not aware of but could Innovaderma IDP be a good fit? Has the skinny tan brand, a stable of direct to consumers, a hair dye brand, men’s grooming and a couple of lines that don’t produce much revenue. They outsource production so there could be economies of scale and they are dealing in the same markets and customers. Back of house synergies and fills in on product gaps in CRLs products. Has a current market cap of 9m on sale of last year 13.3m. Not here to ramp as I hold both companies but I was intrigued by the comments at the end of the presentation around the growth, products they wanted to infill and the want to go DTC.
chop50: Boonboon, how so? The majority of the employees are not in the UK! They go , kiss IDP bye bye and our shareholdings with it. Laughable that people think that an international company has to have all directors in one country! Sheesh!
lord loads of lolly: Not really a conflict of interest. Just a potential lowball buyout threat. But even if this is his ultimate aim, I imagine he'd want to see the company make significant progress first. Which should mean the share price goes a lot higher than current levels within the next year or two.
kenwright: RNS out today but not showing in the monitor lists..... InnovaDerma PLC US distributor appointed and Nuthing launch in AUS 28/09/2020 7:00am RNS Non-Regulatory TIDMIDP InnovaDerma PLC 28 September 2020 LEI: 213800WRAP6W8VDL6B38 InnovaDerma PLC ("InnovaDerma" or the "Company") InnovaDerma appoints US distributor Nuthing ranged in Priceline, Australia InnovaDerma (LSE: IDP), a UK developer of beauty, personal care and life sciences products, is pleased to provide the following update: US Distributor The PCA Group (PCA), a long-established US based beauty brands distributor, has been appointed as the exclusive distributor for all the Company's topical brands in North America and South America. The distribution agreement will include all major retailers and e-commerce companies in these regions including Amazon. Established 25 years ago and employing more than 600 people worldwide, PCA works with global and disruptive brands including Revlon, Too Faced, Elizabeth Arden and Burts Bees. The Company will continue to market and sell its brands through its DTC platform and via the QvC television shopping network. Nuthing Following positive responses from Priceline, all nine Stock Keeping Units of Nuthing, the Company's hair removal brand are now available to purchase in 152 stores and online. Priceline has 474 stores nationwide and is Australia's largest beauty retailer and securing initial distribution in their larger format stores is an important step forward in the Company's strategy to diversify outside the UK. The brand's entry into Australia is its first overseas following the successful launch in the UK earlier this year, in c.800 Superdrug stores, online and on the Company's DTC platform. Nuthing is the Company's latest skin-care innovation brand which is much less seasonal and complementary to Skinny Tan, offering the opportunity to cross target promotions Joe Bayer, Executive Chairman of InnovaDerma, said: " We are very pleased to have appointed PCA as our distributor in the Americas for all our topical brands. They have an excellent track record in distributing well-established and disruptive beauty brands to major retailers and online platforms and we look forward to working with them in gaining a major foothold in these markets. "We enjoy a strong relationship with Priceline in Australia and it is particularly pleasing to have secured distribution for Nuthing, a testament to this high quality, innovative and well-positioned brand which only launched in February this year. "These agreements are key to furthering our strategic aim of diversifying revenue streams outside the UK and we look forward to making further inroads in these significant markets." Further enquiries InnovaDerma Joe Bayer +61 (0)3 9863 8030 finnCap Ltd Geoff Nash/Kate Bannatyne +44 (0)207 220 0500 Alice Lane/Manasa Patil - Corporate Broking --------------------------- TB Cardew Shan Shan Willenbrock/Tom Allison + 44 (0)20 7930 0777 Olivia Rosser --------------------------- This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy. END
shandypants2: Boon - great summary and agree with all your comments. Still a 1 brand, 1 country company really and need to diversify more. Hopefully nuthing will do this, as not sure about Roots IMHO. C+L doesn't seem any different to other mens brands and this market has got quite competitive over the last few years. Maybe Prolong will be the surprise package. Also agree with International expansion - US retail deal for ST would be nice plus nuthing being rolled out in various countries as company alluded to in previous RNSs. Considering covid happened at exactly the worst time for IDP performance in 2020 has been very good and it is reassuring that there were no staff cuts etc required and bank loans or placings to sure up the balance sheet. However, unfortunately this is an unloved sector so can't see much short term share price action. Do think we will see £2m PBT in next 2 years and a share price nearer £1.50 IMHO.
lord loads of lolly: boonboon - I agree with a lot of what you say. Can't see a £4 share price happening any time soon though. Also, I think you underestimate the potential of Prolong. Its high share price and margin mean it has huge potential. And wasn't a significant Asian deal already on the horizon once necessary approvals had been obtained?
teddy boy1: When the IDP share price spikes as it has done in the last 2 or 3 days you can be sure that this will shortly be followed by a fall Our happy band of IDP traders have great big smiles on their faces, licking their lips in anticipation. Just see if a right,yet again!
Innovaderma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210126 03:48:22